New obesity drug SRSD384 enters human testing
Disease control
Not yet recruiting
This study tests a new injectable drug called SRSD384 in 78 overweight or obese adults. In the first part, participants receive a single dose of SRSD384 alone. In the second part, they receive SRSD384 combined with another weight-loss drug, tirzepatide. The main goal is to check …
Phase: PHASE1, PHASE2 • Sponsor: Sirius Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC